Indeed, in a previously published article from Mazzola and colleagues, PET-PSMA-guided MDT seems to offer an advantage in terms of ADT-free survival if compared to PET-choline-guided SBRT in the oligorecurrent PC [23]. Here, FOLH1 is linked to pachyonychia congenita.